Market capitalization | $490.10m |
Enterprise Value | $118.63m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.34 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-99.98m |
Free Cash Flow (TTM) Free Cash Flow | $-74.91m |
Cash position | $372.78m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Terns Pharmaceuticals Inc forecast:
8 Analysts have issued a Terns Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.90 -0.90 |
22%
22%
|
|
EBITDA | -99 -99 |
5%
5%
|
EBIT (Operating Income) EBIT | -100 -100 |
5%
5%
|
Net Profit | -88 -88 |
4%
4%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Head office | United States |
CEO | Amy Burroughs |
Employees | 66 |
Founded | 2017 |
Website | www.ternspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.